Clinical trials: Hair Problems
Hair Care, Hair Loss
Olistic_2025 for Hair Loss, Hair Growth, and Skin Improvement
The goal of this randomized, double-blind, placebo-controlled clinical trial is to find out whether daily oral intake of the nutraceutical Olistic Next Women can reduce hair loss, improve hair growth and quality, and improve…
- Conditions
- Hair Care, Hair Loss, Female Pattern Hair Loss
- Trial name
- NCT07300813
- Testing
- Olistic Next Women
- Where
- Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bionos Biotech S.L.
Androgenetic Alopecia
Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
The purpose of this study is to measure the hair growth response to topical NEOSH101 when applied twice daily to the balding scalp for 16 weeks.
- Trial name
- NCT00418730
- Testing
- tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
- Where
- Germany
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Neosil, Inc.
Alopecia Areata
A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata
The purpose of this study is to determine if receiving sub-cutaneous injections of a medication called abatacept causes regrowth of hair in people with alopecia areata.
- Trial name
- NCT01917058
- Testing
- Abatacept
- Where
- United States
- Sponsor
- Columbia University
Alopecia Areata, Alopecia Totalis
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
To determine the efficacy of oral Tofacitinib in the treatment of moderate to severe alopecia areata, totalis and universalis at tertiary care hospital of Karachi, Pakistan.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT06278402
- Testing
- Tofacitinib
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Jinnah Hospital
Severe Alopecia Areata
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss.
- Trial name
- B7981028 (NCT07029828)
- Testing
- Ritlecitinib higher dose, Ritlecitinib lower dose
- Where
- 67 sites in United States, China and 7 more
- Volunteers
- 140 people
- Sponsor
- Pfizer
Alopecia Areata
European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, severe alopecia areata.
- Trial name
- NCT05041803
- Testing
- CTP-543
- Where
- 39 sites in France, Germany and 3 more
- Volunteers
- 407 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Hair Loss/Baldness, Alopecia
Autologous Adipose-Derived Adult Stromal Vascular Cell Transplantation for Alopecia
Most common forms of hair loss (alopecia) are caused by aberrant hair follicle cycling and changes in hair follicle morphology. However, current treatments for alopecia do not specifically target these processes.
- Trial name
- A-ADSVC-CT-A (NCT03427905)
- Testing
- Lipoaspiration, Transplantation
- Where
- Lebanon
- Volunteers
- 20 people
- Sponsor
- Lebanese University
Androgenic Alopecia, Hair Loss/Baldness
Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia
The goal of this study is to determine if Xtresse' gummy is safe and may help regrow hair in men with androgenic alopecia (common pattern hair loss).
- Conditions
- Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
- Trial name
- NCT07637071
- Testing
- Xtressé Hair Growth Gummies
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Hair Thinning, Hair Loss
Impact of a Topical Cosmetic Product on Women's Hair
The proposed pilot study will investigate the impact of a daily topical nutritional product applied to women's hair, specific to perceived hair quality and overall well-being.
- Trial name
- NCT06060834
- Testing
- Topical Botanical Agent
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Memphis
Alopecia Areata
Efficacy of Fractional CO2 Laser as a Mono- or Adjuvant Therapy for Alopecia Areata
Alopecia areata is a non-scarring hair loss disorder that affects both sexes equally. Incidence of the disease varies for different populations and in different studies, with global incidence ranging from 0.57% to 3.8%.
- Trial name
- NCT04003376
- Testing
- fractional carbon dioxide laser alone, Triamcinolone Acetonide 10mg/mL, platelet rich plasma
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Alopecia Areata(AA)
Impact of NR3C1 rs41423247 (BclI) Polymorphism on Disease Severity in Alopecia Areata
Alopecia areata is an autoimmune, non-scarring hair loss disorder with multifactorial pathogenesis. The glucocorticoid receptor gene (NR3C1) plays an essential role in immune regulation and inflammatory response.
- Trial name
- NR3C1 and AA (NCT07455708)
- Where
- Egypt
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Benha University
Alopecia Areata
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
This study evaluates the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss.
- Trial name
- NCT07133308
- Testing
- Deuruxolitinib
- Where
- 64 sites in United States, Canada
- Volunteers
- 355 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Alopecia Areata, Alopecia Totalis
Systemic Treatments for Alopecia Areata Registry
A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Hair Loss
- Trial name
- STA2R (NCT06283316)
- Where
- Netherlands
- Volunteers
- 10,000 people
- Sponsor
- Erasmus Medical Center
Alopecia Areata
1565nm Non-ablative Fractional Laser Treat Alopecia Areata
The goal of this clinical trial is to evaluate and explore the mechanism of 1565-nm non-ablative fractional laser in the treatment of alopecia areata.
- Trial name
- NCT05744505
- Testing
- 1565nm Non-ablative Fractional Laser
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Androgenetic Alopecia, Coronavirus Disease 2019
Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia.
- Conditions
- Androgenetic Alopecia, Coronavirus Disease 2019, Covid19, Male Pattern Baldness
- Trial name
- NCT04898166
- Where
- Pakistan
- Volunteers
- 300 people
- Sponsor
- Syeda Mahanum Ali
Androgenetic Alopecia
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
The study is designed to evaluate safety and efficacy of PP405 in adult female participants with androgenetic alopecia
- Trial name
- AWAKENING (NCT07907783)
- Testing
- PP405 0.05% Topical Gel, Vehicle Topical Gel
- Volunteers
- 200 people
- Sponsor
- Pelage Pharmaceuticals, Inc.
Alopecia Areata
Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser
Alopecia areata (AA) an autoimmune disorder of hair follicles results in varying degrees of scalp, facial and body hair loss. Clinically, patients' presentation varies from patchy circumscribed scalp involvement to total body and…
- Trial name
- NCT06239324
- Testing
- Latanoprost
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Egymedicalpedia
Androgenetic Alopecia
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
- Trial name
- NCT02275351
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 24 sites in United States
- Volunteers
- 302 people
- Sponsor
- Biosplice Therapeutics, Inc.
Alopecia Areata
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.
The primary objective of this study was to evaluate the change in serum interferon gamma and Interleukin-15 levels before and after use of oral drug baricitinib therapy.
- Trial name
- Alopecia (NCT07645430)
- Testing
- Baricitinib 4 MG Oral Tablet
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Benha University
Psoriasis, Alopecia Areata
Development and EValuation of an Online Intervention to Reduce Self-Stigma in People With Visible Chronic Skin disEases
This project aims to develop and evaluate an online intervention to prevent and/or reduce self-stigma in German patients with visible chronic skin diseases.
- Conditions
- Psoriasis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
- Trial name
- DEVISE (NCT06324695)
- Testing
- HautKompass
- Where
- 12 sites in Germany
- Volunteers
- 298 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf